{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:41:55Z","timestamp":1780324915247,"version":"3.54.1"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MH CZ-DRO-VFN64165"],"award-info":[{"award-number":["MH CZ-DRO-VFN64165"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>The objective of this systematic review is to evaluate the efficacy and safety of antigen-specific tolerance-inducing therapeutic approaches (products based on peptides, DNA and T cells) versus placebo or other comparators, where possible, in adult multiple sclerosis (MS) patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>PubMed, CINAHL, Web of Science, Cochrane and International Clinical Trials Registry Platform, ClinicalTrials.gov were searched for published and unpublished studies. Screening, critical appraisal, and data extraction for included studies were carried out by two independent reviewers. For efficacy, phase I, II and III clinical trials (randomized\/non-randomized; double blind\/single blind\/unblinded; single-center\/multicenter; single-arm\/two-arm) and for safety, phase I, II and III clinical trials (randomized\/non-randomized; double blind\/single blind\/unblinded; controlled\/uncontrolled; single-center\/multicenter; single-arm\/two-arm) were included. Observational studies (cross-sectional studies, cohort studies, case studies\/reports etc), review articles, systematic reviews, meta-analysis, preclinical and pilot studies were excluded. All included studies were critically appraised using standardized JBI tools, with no exclusions based on methodological quality. Where possible, studies were pooled in statistical meta-analysis, presented in tabular format, and accompanied by narrative synthesis. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach for grading the certainty of evidence.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Search yielded 2644 results and in total 26 studies were included in the final analysis. Twelve studies were RCTs and 14 were quasi-experimental. In total, there were 1427 subjects from the RCTs, and 314 from non-RCTs. Sample size of studies ranged from 10 to 612 patients. All studies included adult patients, principally aged 18\u201355\/65 years. Critical appraisal scores for the RCTs were in the range 31% to 92%. For quasi-experimental studies, critical appraisal scores were in the range 45% to 78%. Due to high heterogeneity of the studies, efficacy of all antigen-specific treatment remained ambiguous. For all three types of treatment, there was no statistical difference in occurrence of adverse effects (AEs) between the treatment- and placebo-related AEs (for DNA-based treatment RR was 1.06 (0.94\u20131.10), p\u2009=\u20090.334; for peptides-base treatments RR was 1.04 (0.90\u20131.08), p\u2009=\u20090.115; for T-cells-based treatments RR was 1.31 (0.97\u20131.76), p\u2009=\u20090.08). There were no differences in RR for serious AEs (SAEs) between the treatments either for DNA-based treatment (RR was 0.63 (0.25\u20131.58), p\u2009=\u20090.322) or peptide-based treatment (RR was 0.86 (0.62\u20131.19), p\u2009=\u20090.361). There were no reported SAEs for T cell-based treatments, so meta-analysis for these therapies was not performed. The most frequent AEs were local reactions to injection, such as redness, erythema, pain.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Discussion<\/jats:title>\n<jats:p>Antigen-specific tolerance-inducing therapeutic approaches appeared to be safe. However, the certainty for these results was very low for SAEs in peptide- and DNA-based therapies, whereas it was low for AEs in DNA- and T cells-based therapies and moderate for AEs in peptide-based therapies. The efficacy of antigen-specific therapies remains ambiguous. Larger, well-designed studies with high level quality are needed to ensure ultimate conclusions.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Registration<\/jats:title>\n<jats:p>The registration number provided following registration of the protocol in PROSPERO is \u2018CRD42021236776\u2019.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0320814","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T17:33:27Z","timestamp":1747676007000},"page":"e0320814","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of antigen-specific therapeutic approaches for multiple sclerosis: Systematic review"],"prefix":"10.1371","volume":"20","author":[{"given":"Hatice K\u00fcbra","family":"\u00d6zt\u00fcrk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ond\u0159ej","family":"Slana\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9690-9846","authenticated-orcid":true,"given":"Danica","family":"Michali\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"9","key":"pone.0320814.ref001","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"CA Dendrou","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"14","key":"pone.0320814.ref002","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS","volume":"26","author":"C Walton","year":"2020","journal-title":"Multiple Sclerosis J"},{"issue":"3","key":"pone.0320814.ref003","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1682\/JRRD.2009.07.0096","article-title":"Multiple sclerosis and mobility-related assistive technology: systematic review of literature","volume":"47","author":"A Souza","year":"2010","journal-title":"J Rehabil Res Dev"},{"issue":"9","key":"pone.0320814.ref004","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrneurol.2012.136","article-title":"The benefits of exercise training in multiple sclerosis","volume":"8","author":"RW Motl","year":"2012","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"pone.0320814.ref005","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1177\/0031512517711851","article-title":"Multiple sclerosis: Associations between physical disability and depression are not mediated by self-reported physical activity","volume":"124","author":"H Merkt","year":"2017","journal-title":"Percept Mot Skills"},{"issue":"1","key":"pone.0320814.ref006","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00415-017-8676-8","article-title":"Changes in disability in people with multiple sclerosis: a 10-year prospective study","volume":"265","author":"D Conradsson","year":"2018","journal-title":"J Neurol"},{"key":"pone.0320814.ref007","doi-asserted-by":"crossref","first-page":"102162","DOI":"10.1016\/j.msard.2020.102162","article-title":"A literature review of cost-of-illness studies on the economic burden of multiple sclerosis","volume":"43","author":"M Paz-Zulueta","year":"2020","journal-title":"Multiple Sclerosis Related Disord"},{"issue":"18","key":"pone.0320814.ref008","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000200150","article-title":"The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs","volume":"98","author":"B Bebo","year":"2022","journal-title":"Neurology"},{"issue":"7","key":"pone.0320814.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159129","article-title":"Cost of Illness of Multiple Sclerosis - A Systematic Review","volume":"11","author":"O Ernstsson","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"pone.0320814.ref010","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3111\/13696998.2013.778268","article-title":"The cost burden of multiple sclerosis in the United States: a systematic review of the literature","volume":"16","author":"G Adelman","year":"2013","journal-title":"J Med Econ"},{"issue":"9","key":"pone.0320814.ref011","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/ni1507","article-title":"Multiple sclerosis: a complicated picture of autoimmunity","volume":"8","author":"HF McFarland","year":"2007","journal-title":"Nat Immunol"},{"issue":"9","key":"pone.0320814.ref012","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"CA Dendrou","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"pone.0320814.ref013","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/brainsci10060333","article-title":"Recent advances in antigen-specific immunotherapies for the treatment of multiple sclerosis","volume":"10","author":"O Kammona","year":"2020","journal-title":"Brain Sci"},{"issue":"3","key":"pone.0320814.ref014","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"J Correale","year":"2016","journal-title":"Brain"},{"issue":"3","key":"pone.0320814.ref015","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"J Correale","year":"2017","journal-title":"Brain"},{"issue":"10","key":"pone.0320814.ref016","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(07)70243-0","article-title":"Primary-progressive multiple sclerosis","volume":"6","author":"DH Miller","year":"2007","journal-title":"Lancet Neurol"},{"issue":"3","key":"pone.0320814.ref017","article-title":"Adverse events associated with disease-modifying drugs for multiple sclerosis: a multiregional population-based study","volume":"102","author":"HS Ng","year":"2024","journal-title":"Neurology"},{"issue":"7900","key":"pone.0320814.ref018","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"TV Lanz","year":"2022","journal-title":"Nature"},{"issue":"9","key":"pone.0320814.ref019","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030309","article-title":"Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration","volume":"9","author":"B Willekens","year":"2019","journal-title":"BMJ Open"},{"issue":"4","key":"pone.0320814.ref020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMcibr2032177","article-title":"Antigen presentation by B cells in multiple sclerosis","volume":"384","author":"SS Zamvil","year":"2021","journal-title":"N Engl J Med"},{"issue":"17","key":"pone.0320814.ref021","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1073\/pnas.1820039116","article-title":"Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial","volume":"116","author":"I Zubizarreta","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"pone.0320814.ref022","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn1823","article-title":"Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis","volume":"8","author":"M Bronge","year":"2022","journal-title":"Sci Adv"},{"key":"pone.0320814.ref023","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3389\/fimmu.2018.01169","article-title":"Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials","volume":"9","author":"G Fl\u00f3rez-Grau","year":"2018","journal-title":"Front Immunol"},{"issue":"10","key":"pone.0320814.ref024","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/archneur.64.10.nct70002","article-title":"Induction of Antigen-Specific Tolerance in Multiple Sclerosis After Immunization With DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1\/2 Trial","volume":"64","author":"A Bar-Or","year":"2007","journal-title":"Arch Neurol"},{"issue":"5","key":"pone.0320814.ref025","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.21370","article-title":"Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis","volume":"63","author":"H Garren","year":"2008","journal-title":"Ann Neurol"},{"issue":"9","key":"pone.0320814.ref026","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2013.3022","article-title":"Transdermal application of myelin peptides in multiple sclerosis treatment","volume":"70","author":"A Walczak","year":"2013","journal-title":"JAMA Neurol"},{"issue":"5","key":"pone.0320814.ref027","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ana.22219","article-title":"Immune regulation of multiple sclerosis by transdermally applied myelin peptides","volume":"68","author":"M Jury\u0144czyk","year":"2010","journal-title":"Ann Neurol"},{"issue":"3","key":"pone.0320814.ref028","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000093","article-title":"Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS","volume":"2","author":"HB Streeter","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"pone.0320814.ref029","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005118","article-title":"Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis","volume":"90","author":"J Chataway","year":"2018","journal-title":"Neurology"},{"key":"pone.0320814.ref030","unstructured":"Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L. Chapter 3: systematic reviews of effectiveness."},{"issue":"1","key":"pone.0320814.ref031","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/XEB.0000000000000152","article-title":"The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI)","volume":"17","author":"Z Munn","year":"2019","journal-title":"Int J Evid Based Healthc"},{"issue":"7","key":"pone.0320814.ref032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"3","key":"pone.0320814.ref033","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","article-title":"Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness","volume":"13","author":"C Tufanaru","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"pone.0320814.ref034","volume-title":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]"},{"issue":"10","key":"pone.0320814.ref035","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/80525","article-title":"Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial","volume":"6","author":"L Kappos","year":"2000","journal-title":"Nature medicine"},{"issue":"16","key":"pone.0320814.ref036","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e318233b240","article-title":"A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS","volume":"77","author":"M Freedman","year":"2011","journal-title":"Neurology"},{"issue":"10","key":"pone.0320814.ref037","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/archneur.64.10.nct70002","article-title":"Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1\/2 trial","volume":"64","author":"A Bar-Or","year":"2007","journal-title":"Archives of Neurol"},{"issue":"5","key":"pone.0320814.ref038","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1191\/1352458505ms1225oa","article-title":"A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis","volume":"11","author":"DN Bourdette","year":"2005","journal-title":"Multiple Sclerosis Journal"},{"key":"pone.0320814.ref039","first-page":"954739","article-title":"Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study","volume":"2012","author":"V Yadav","year":"2012","journal-title":"Autoimmune Dis"},{"issue":"6","key":"pone.0320814.ref040","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458511428462","article-title":"A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design","volume":"18","author":"E Fox","year":"2012","journal-title":"Multiple Sclerosis Journal"},{"issue":"5","key":"pone.0320814.ref041","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.21370","article-title":"Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis","volume":"63","author":"H Garren","year":"2008","journal-title":"Ann Neurol"},{"issue":"11","key":"pone.0320814.ref042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143366","article-title":"Therapeutic intervention in multiple sclerosis with alpha B-crystallin: A randomized controlled phase IIa trial","volume":"10","author":"JM van Noort","year":"2015","journal-title":"PloS One"},{"issue":"9","key":"pone.0320814.ref043","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2013.3022","article-title":"Transdermal application of myelin peptides in multiple sclerosis treatment","volume":"70","author":"A Walczak","year":"2013","journal-title":"JAMA Neurol"},{"issue":"8","key":"pone.0320814.ref044","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1468-1331.2006.01533.x","article-title":"Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment","volume":"13","author":"K Warren","year":"2006","journal-title":"Eur J Neurol"},{"issue":"12","key":"pone.0320814.ref045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050478","article-title":"T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial","volume":"7","author":"D Karussis","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"pone.0320814.ref046","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1212\/WNL.54.7.1414","article-title":"A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis","volume":"54","author":"DE Goodkin","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"pone.0320814.ref047","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clim.2004.06.004","article-title":"T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients","volume":"113","author":"A Achiron","year":"2004","journal-title":"Clin Immunol"},{"key":"pone.0320814.ref048","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40259-020-00462-7","article-title":"Administration of CD4+CD25highCD127-FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study","volume":"35","author":"K Chwojnicki","year":"2021","journal-title":"BioDrugs"},{"key":"pone.0320814.ref049","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s13311-016-0448-0","article-title":"CD206-targeted liposomal myelin basic protein peptides in patients with multiple sclerosis resistant to first-line disease-modifying therapies: a first-in-human, proof-of-concept dose-escalation study","volume":"13","author":"A Belogurov","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"2","key":"pone.0320814.ref050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.clim.2009.01.005","article-title":"Autologous attenuated T-cell vaccine (Tovaxin\u00ae) dose escalation in multiple sclerosis relapsing\u2013remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies","volume":"131","author":"B Loftus","year":"2009","journal-title":"Clinical Immunology"},{"key":"pone.0320814.ref051","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/PL00007867","article-title":"T cell vaccination in multiple sclerosis: results of a preliminary study","volume":"249","author":"JZ Zhang","year":"2002","journal-title":"J Neurol"},{"issue":"5","key":"pone.0320814.ref052","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.4049\/jimmunol.152.5.2510","article-title":"Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides","volume":"152","author":"DN Bourdette","year":"1994","journal-title":"J Immunol"},{"issue":"22","key":"pone.0320814.ref053","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124714","article-title":"Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis","volume":"3","author":"MP Pender","year":"2018","journal-title":"JCI Insight"},{"key":"pone.0320814.ref054","unstructured":"Bar-Or A, Pender M, Hodgkinson S, Broadley S, Lindsey J, Ioannides Z, et al. Phase I open-label extension and imaging data for ATA188, an allogeneic Epstein-Barr virus-targeted multiple sclerosis immunotherapy. 2021."},{"issue":"3","key":"pone.0320814.ref055","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jnr.1078","article-title":"Vaccination with a CDR2 BV6S2\/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis","volume":"64","author":"EE Morgan","year":"2001","journal-title":"J Neurosci Res"},{"issue":"1","key":"pone.0320814.ref056","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2567.2007.02703.x","article-title":"Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis","volume":"123","author":"AA Vandenbark","year":"2008","journal-title":"Immunology"},{"key":"pone.0320814.ref057","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10517-008-0237-9","article-title":"Induction of antiidiotypic immune response with autologous T-cell vaccine in patients with multiple sclerosis","volume":"146","author":"I Ivanova","year":"2008","journal-title":"Bull Exp Biol Med"},{"key":"pone.0320814.ref058","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1749-6632.1996.tb21132.x","article-title":"Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial","volume":"778","author":"MJ Hohol","year":"1996","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"pone.0320814.ref059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-017-0549-6","article-title":"Ibrutinib, a Bruton\u2019s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma","volume":"36","author":"J Wang","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"pone.0320814.ref060","doi-asserted-by":"crossref","first-page":"102873","DOI":"10.1016\/j.autrev.2021.102873","article-title":"Safety and immunological proof-of-concept following treatment with tolerance-inducing cell products in patients with autoimmune diseases or receiving organ transplantation: A systematic review and meta-analysis of clinical trials","volume":"20","author":"B Willekens","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"6578","key":"pone.0320814.ref061","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1126\/science.abm7930","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"375","author":"WH Robinson","year":"2022","journal-title":"Science"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0320814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T17:33:40Z","timestamp":1747676020000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0320814"}},"subtitle":[],"editor":[{"given":"Tanja","family":"Grubi\u0107 Kezele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0320814","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}